Unicycive Therapeutics Inc UNCY

US Biotechnology

$4.55 ▼ -1.94% ($-0.09)

⚡ High Volume

Open $4.66

Prev Close $4.64

Day Range $4.28 – $4.70

52W Range $3.75 – $8.74

Market Cap $126.74M

Beta 1.81

EPS (TTM) $-1.62

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2021-06-17
Shares Out.	26,700,000
Website	unicycive.com/ ↗
Phone	16503840642
Employees	22
Revenue	$0
Gross Profit	$0
Net Income	-$1.7M
Free Cash Flow	-$27.8M
Total Assets	$72.0M
Total Liabilities	$18.8M
Equity	$53.3M

About Unicycive Therapeutics Inc

Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.

Unicycive Therapeutics Inc is a publicly traded company under the ticker symbol UNCY on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.